Investment Pitches

Pitch Summary:
Despite recent stock price declines due to concerns over potential drug price controls and tariffs, IQVIA Holdings remains a compelling investment. The company's Contract Research Organization segment outperformed peers, and its Technology and Analytic Solutions segment is performing well. With shares trading near an all-time low multiple and increased share repurchases, IQVIA presents an attractive opportunity for long-term investors.

BSD Analysis:
IQVIA Holdings faces short-term headwinds from potential regulatory changes and budget cuts affecting the biopharma sector. However, its strong performance in key segments and strategic share repurchases signal management's confidence in the company's future. The stock's current valuation, near historical lows, offers a favorable entry point for investors. IQVIA's ability to maintain industry-leading margins and its focus on technology-driven solutions position it well for future growth. As biopharma R&D spending stabilizes, IQVIA is likely to benefit from its robust service offerings and global reach. Investors should consider the company's long-term growth prospects and potential for margin expansion as key factors in their investment decision.

Pitch Summary:
Coinbase Global's current valuation appears unsustainable given its market cap now exceeds that of traditional exchanges like CME and ICE, which handle a broader range of essential commodities and derivatives. Despite favorable crypto legislation, Coinbase's market share and revenue growth have stagnated, suggesting it struggles to capitalize on industry trends. The competitive landscape, with major financial institutions entering the crypto space, further challenges Coinbase's ability to maintain its current valuation.

BSD Analysis:
Coinbase's market cap of $107 billion surpasses that of established exchanges like CME and ICE, raising questions about its long-term value proposition. While its revenue has grown to $6.7 billion on a trailing twelve-month basis, this is still below its 2021 peak of $7.8 billion, indicating limited growth momentum. The company's profitability also lags behind previous highs, with net income at $1.5 billion, down from $3.1 billion in 2021. The competitive pressure from both crypto-native and traditional financial institutions, such as JPMorgan and BlackRock, intensifies as they develop their own crypto products. Although the GENIUS Act could potentially benefit the crypto industry, its impact on Coinbase remains uncertain. Given these factors, the stock's current valuation seems disproportionate to its growth prospects and market position.

Pitch Summary:
Garmin Ltd. has demonstrated robust growth across its diverse business segments, particularly in Fitness and Outdoor, driven by the increasing demand for smartwatches and wearables. Despite this, the company's current valuation appears stretched, with both GAAP and Non-GAAP P/E ratios exceeding historical averages and sector medians. While Garmin's innovation in AI-driven services and its strong balance sheet are commendable, the stock's current price may not justify its growth prospects, leading to a cautious stance on further investment.

BSD Analysis:
Garmin's strategic focus on innovation, particularly in AI-enhanced services like Garmin Connect+ and inReach SOS, positions it well for future growth. However, the competitive landscape in the Fitness segment, with formidable players like Apple and Google, poses significant challenges. Garmin's commitment to R&D is crucial to maintaining its competitive edge. The company's financial health is strong, with over $2 billion in cash and a history of shareholder returns through dividends and buybacks. Yet, the valuation concerns are underscored by a reverse DCF analysis, suggesting a required growth rate of 15% to justify current prices, which seems optimistic given market conditions. Investors should monitor tariff impacts and competitive pressures closely, as these could affect Garmin's ability to sustain its growth trajectory.

Pitch Summary:
We sold Zoetis, as concerns continue to grow about competitive entrants in the dermatology and parasiticides animal health marketplace. While the company has continued to execute well in the face of new entrants, we believe that this will continue to be an overhang on the stock in the near to medium term. Given the premium valuation versus other areas in health care, we believe there is more upside eLondon Stock Exchangewhere and are exiting our position in the stock.

BSD Analysis:
Zoetis is the animal health empire with economic characteristics pharma companies would kill for: sticky customer relationships, recurring demand from both pets and livestock, and minimal patent-cliff drama. Its dermatology franchise continues to outperform, vaccines are steady, and new products keep replenishing the pipeline without the volatility of human drug cycles. Pricing power is real in vet channels, and companion animal demand has proven far more resilient than skeptics assumed post-pandemic. With margins at the high end of healthcare and growth visibility extending years out, Zoetis remains one of the cleanest long-term compounders in life sciences — still trading below its strategic value.

Pitch Summary:
We sold Expedia Group due to a higher risk of a recession following the significant increase in global tariffs, which can be expected to reduce overall levels of economic activity. In addition, the negative impact on the wealth effect due to potentially declining equity markets will likely impact demand for retail travel. Travel is among the most discretionary spend categories within the consumer discretionary sector.

BSD Analysis:
Expedia has spent years cleaning up its tech stack and brand sprawl, and the payoff is finally showing up in its cost structure and conversion metrics. Travel demand remains robust globally, and Expedia’s unified loyalty platform is becoming a real moat instead of a missed opportunity. Vrbo is stabilizing, B2B partnerships are quietly becoming a margin engine, and operating discipline is evident across the P&L. Expedia will always trade with some volatility because it’s tied to global travel, but today’s Expedia is leaner, more automated, and more profitable than the market gives it credit for. When the next travel upcycle hits, this model has more torque than investors realize.

Pitch Summary:
Chubb detracted from performance in the second quarter, primarily due to a market rotation out of defensive names amid a broader market rally led by technology and other cyclical sectors. The company’s first quarter earnings report showed slowing growth in P&C net written premiums, raising concerns about potentially softening pricing trends in its commercial insurance business following several years of strong performance.

BSD Analysis:
Chubb is the gold-standard underwriter in a world where discipline is increasingly rare. While competitors chase premium at any price, Chubb keeps writing profitable business and walking away from junk risk — and the combined ratios prove it. Rising rates are a tailwind for investment income, but the real story is Chubb’s ability to consistently price above loss cost inflation. Its global footprint in commercial, specialty, and high-net-worth personal lines gives it a moat that smaller carriers can’t replicate. The balance sheet is bulletproof, capital return is strong, and organic growth is surprisingly durable. Chubb is what every insurer wishes it could be: boring, ruthless, and relentlessly profitable.

Pitch Summary:
Becton Dickinson detracted from relative performance in the second quarter following a worse-than-expected fiscal quarter earnings report in which the company felt the impact of cuts to the National Institutes of Health (NIH) budget and uncertainty around future cuts. Furthermore, forward earnings and revenue guidance were reduced to reflect the continued weakness in funding for biosciences R&D and the expected impact of tariffs.

BSD Analysis:
BD is the industrial-strength circulatory system of global healthcare — syringes, infusion sets, diagnostics, and lab automation that hospitals cannot function without. It’s a scale-driven consumables machine with a growing portfolio of higher-tech offerings, from drug-delivery platforms to advanced molecular diagnostics. After years of integration cleanup, BD finally has a simpler, more profitable operating model, and the steady uptick in elective procedures is flowing straight into earnings. With recurring consumables as its backbone and innovation seeding new growth, BD is one of the medtech names with the lowest downside and surprising operating leverage on the upside. The market still treats it like a plodder — but BD is steadily upgrading itself.

Pitch Summary:
Broadcom contributed to performance in the second quarter, as the company reported strong quarterly results for its AI compute and networking business, as well as its VMware segment. The company also provided positive commentary on the setup for the AI-related silicon business units for the rest of 2025, and also for 2026, as strong customer demand for AI silicon for training and inference continues.

BSD Analysis:
Broadcom is running a capital allocation clinic: buy chokepoint assets, milk them efficiently, reinvest where the tech curve bends upward, and cut everything eLondon Stock Exchange. Its custom silicon business is booming as hyperscalers demand domain-specific AI chips, and Broadcom’s networking gear sits at the heart of AI cluster architecture. VMware is rapidly becoming a margin multiplier, not an integration headache. The company’s discipline is unmatched — it only plays in markets where it can dominate, raise prices, and defend cash flow. Broadcom isn’t a semiconductor company anymore; it’s a compute-and-connectivity conglomerate with private-equity precision. The stock still isn’t fully priced for how structurally strong this model has become.

Pitch Summary:
Oracle contributed to performance in the second quarter, as the company reported strong quarterly results that highlighted continued strong demand for the company’s OCI infrastructure, sustained growth in the company’s SaaS apps business, and accelerating growth trends in the cloud database segment. Management highlighted RPO growth of over 100%, which speaks to continuing demand for Oracle’s infrastructure and software products over a multi-year period.

BSD Analysis:
Oracle has quietly engineered one of the most impressive second acts in enterprise software. While rivals chase hype cycles, Oracle is stacking long-duration AI infrastructure deals with hyperscalers who need massive, performant GPU clusters now, not in two years. OCI’s performance-per-dollar edge is real, proven, and increasingly impossible for procurement teams to ignore. The beauty is that Oracle’s legacy database and ERP franchises still vomit cash, effectively self-funding the AI land grab. Meanwhile, the company’s global data center expansion is happening at a pace few thought Oracle capable of. Investors keep waiting for the pivot to break down — but the numbers keep getting better. Oracle is the AI infrastructure partner hiding in plain sight.

Pitch Summary:
Continuing with that sentiment, we added aggressively to Lam Research and ASML in April. These were relatively new and small positions that we established at the end of the first quarter, and we were able to substantially lower our cost basis with the shares trading 25–30% off of their February highs. Shares in both companies have appreciated by a large margin since and are trading even higher than our initial purchase price. Surely, Lam’s underlying intrinsic value did not oscillate so violently. These companies are perceived to be highly sensitive to trade policy due to the overwhelming majority of their revenues coming from Asia, and investors react strongly to any announcement or rumor of export restrictions. However, semiconductors must be produced somewhere in the modern world. If not China or Taiwan, it will be somewhere eLondon Stock Exchange, and those foundries will undoubtedly still be customers of ASML and Lam.

BSD Analysis:
ASML is the most important manufacturing company in the world — the sole provider of EUV lithography, the gatekeeper of advanced semiconductors, and a geopolitical asset disguised as a business. Every chipmaker on Earth depends on ASML’s roadmap, and demand remains unstoppable even with export restrictions. Backlog visibility runs years, margins are elite, and the company’s pricing power is unmatched because there is no substitute. AI is driving a new node race, and ASML gets paid every time fabs invest. This is a monopoly on the future of compute.

Pitch Summary:
Continuing with that sentiment, we added aggressively to Lam Research and ASML in April. These were relatively new and small positions that we established at the end of the first quarter, and we were able to substantially lower our cost basis with the shares trading 25–30% off of their February highs. Shares in both companies have appreciated by a large margin since and are trading even higher than our initial purchase price. In particular, Lam has almost doubled from its April lows in just two months. Surely, Lam’s underlying intrinsic value did not oscillate so violently. These companies are perceived to be highly sensitive to trade policy due to the overwhelming majority of their revenues coming from Asia, and investors react strongly to any announcement or rumor of export restrictions. However, semiconductors must be produced somewhere in the modern world. If not China or Taiwan, it will be somewhere eLondon Stock Exchange, and those foundries will undoubtedly still be customers of ASML and Lam.

BSD Analysis:
Lam is the semiconductor-equipment giant sitting at the center of the HBM and advanced-node explosion. Etch and deposition steps are only getting more complex, and Lam owns the hardest parts of the stack. The company’s service revenue, backlog visibility, and exposure to memory recovery give it a multi-year upgrade cycle. AI infrastructure buildouts will drive enormous demand for Lam’s tools. The stock still trades like a cyclical — but this is secular.

Pitch Summary:
Eagle is a producer of building materials, primarily cement and wallboard. In other words, they quarry rocks and minerals and transform them into the most basic construction products. I always write about how we are trying to buy quality businesses at modest prices, which leads to a fair question: can a cement producer be considered high quality? There are several factors that go into determining business quality, but the two most important in my mind are: 1) the returns on incremental invested capital of a business, and 2) the durability of these returns. Many businesses can generate high returns for a short period of time, but the forces of competition inevitably drive these returns down. These high returns mean very little if they only last for a few years. Barriers to entry must exist to protect these returns and are thus the most important aspect of business quality. To clarify a common misconception, cement is not concrete; it is instead the key binding agent in concrete, without which modern construction would not be possible. Anyone can mix cement and aggregate together to form concrete, but cement production is much more involved. It is not a product that shoots the lights out with exceptional growth or extreme capital efficiency, as volumes grow roughly in line with population, and the plants require significant ongoing maintenance to stay fluidly operational. Specifically, to produce cement, limestone is crushed and mixed with other sediment. This mix makes its way through a series of preheaters and eventually to a kiln, where the temperature must rise to over 1400°C, or 2500°F, to transform the mixture into an intermediate product known as clinker. This clinker is subsequently mixed with a small amount of gypsum and crushed into the fine powder that we know as cement. In other words, there is a large amount of heavy machinery involved that is working under very intensive loads. Cement plants are capital intensive, emissions intensive, loud, and eyesores for the general public. These plants account for ~8% of all carbon emissions worldwide and are generally placed on the fringes of population centers. In 2010, NESHAP was enacted in the United States. This brought a slew of environmental regulations, subjecting cement plants to emissions limits that significantly increased plant expenses. These compliance costs led many smaller or older plants to close and made it cost prohibitive to open a new plant. Today, it would take billions of dollars and nearly a decade of permitting and construction to open a greenfield plant. Typically, only one or two cement plants can effectively serve each market due to the proximal nature of the product. Cement has a low average net selling price per ton, and it becomes prohibitively expensive to ship far distances. Eagle estimates that the average cement plant can competitively serve markets within only a 150-mile radius. As a consequence of regulation, there are fewer cement plants now than there were fifteen years ago despite higher demand. This persistent supply and demand imbalance has resulted in newfound pricing power. Eagle’s operations are almost entirely shielded from coastal imports. Eagle’s returns on incremental invested capital have approximated 30% and they have repurchased more than a third of their outstanding shares.

BSD Analysis:
Eagle Materials is the U.S. cement and wallboard monster riding the strongest construction and infrastructure cycle in years. With supply tight and demand firm, pricing is powerful and margins are spectacular. Wallboard demand tracks housing construction, which has a multi-year backlog. Cement capacity is constrained nationally, giving Eagle serious long-term pricing leverage. This is a pure-play U.S. materials compounder with exceptional economics.

Pitch Summary:
Türkiye Sigorta (TSG) is Turkey’s largest non-life insurer, created in 2020 by merging three state-bank insurers (Ziraat, Halk, Güneş) under the sovereign wealth fund. The pitch argues TSG has a structural moat from unrivaled distribution (5,200 bank branches at state banks, 3,500 PTT post offices, e-Gov integration), giving it the sector’s lowest expense/commission ratios and sticky renewal behavior. While Turkey’s P&C market has been distorted by high inflation, price caps in mandatory lines (MTPL, DASK, TARSİM), and FX pass-through on imported repair/medical inputs, TSG has still taken share to ~16% of GWP, aided by regulator preference and competitors’ capital strain. The company is intentionally exiting capped MTPL and shifting to discretionary, freely priced lines (motor own damage, health, specialty), where it reports materially better combined ratios and rapid growth (health premiums up ~4–5× since 2021; specialty +30% y/y). On solvency/capital, recent rule tightening (Solvency-II-like migration, governance/IT mandates) and SEDDK enforcement have pressured small/foreign players; TSG retains ~200% solvency and ~185% capital adequacy, pays a reliable dividend, and can expand when others retrench. The second leg of the thesis is macro: with policy rate ~46% and CPI ~35% trending lower under the new CBRT regime, TSG is deploying its ~₺60–72bn float into short-duration govvies at ~35–46% nominal, setting up multi-year positive real returns as inflation decelerates before rates are cut. The author models GWP of ~₺160/₺220/₺260bn (’25/’26/’27), combined ratio improving toward 90%, and float AUM compounding ~20% annually—implying ~$0.06 2027 EPS (USD) despite assuming further TRY depreciation. On these numbers the shares trade at ~4× 2027E earnings (~1.1× 2026E BV) with a ~4% dividend yield; SOTP suggests investors can “pay for the float and get underwriting free” (or vice-versa). Optionality includes further industry consolidation (regulatory takeovers, exits), continued re-mix to discretionary lines, and a re-rating if disinflation sticks and foreign flows return. Key risks are a sharper TRY devaluation, policy reversals, catastrophe losses (flood/frost), or slower health-line normalization; mitigants include domestic reinsurance pools (Türk Re, TARSİM/DASK caps) and TSG’s cost edge. Overall, the idea frames TSG as the scale consolidator in a still-underpenetrated market (insurance density far below developed peers) with macro tailwinds to the investment book.

BSD Analysis:
Bull: State-aligned distribution (state banks/PTT/e-Gov) yields lowest CAC and sector-best expense ratio; regulatory tightening and solvency pressure accelerate consolidation to TSG; mix shift from capped MTPL to MOD/health/specialty lifts combined ratio; float earns positive real rates as CPI falls before policy cuts. Skeptic: TRY devaluation could swamp USD results; health line only recently near breakeven; catastrophe volatility (flood/frost) and provisioning/discount-rate effects; state ownership could impose quasi-public objectives. Differentiator: Connects Turkey’s disinflation path and rate-cut lag to multi-year real returns on float while showing how mandatory-line dominance created “regulatory goodwill” now being converted into profitable discretionary share gains.

Pitch Summary:
Bumble is an online dating platform facing both structural business model limitations and emerging technological disruption risks. While the stock has rebounded 90% since April and trades near all-time lows, the author argues the recent turnaround narrative—led by the returning founder-CEO and focused on cutting costs and purging bots—is fundamentally flawed. The company’s female-first dynamic structurally limits engagement from men, creating a self-reinforcing churn problem that cannot be solved with user experience tweaks. More concerningly, the rapid rise of AI companionship apps suggests terminal value risk for traditional dating platforms, as male users increasingly substitute toward AI-based interaction. The result could mirror Chegg’s collapse post-AI disruption, where engagement and monetization erode faster than expected. Despite short-term catalysts such as cost optimization and modest product improvements, Bumble’s long-term value proposition appears impaired, and any short-term rally likely presents an attractive short entry.

BSD Analysis:
Bumble’s core user experience problem—reliant on women initiating contact—creates inherent gender imbalance and limits its ability to scale or improve engagement sustainably. The “turnaround” under the returning founder may offer temporary headline relief but fails to address the structural mismatch between product design and user psychology. More critically, AI companionship tools are accelerating, offering a cheaper, lower-friction substitute for digital dating, particularly among younger men. This dynamic threatens Bumble’s long-term relevance and monetization potential, echoing the disruption of legacy online education players like Chegg by generative AI. While short squeezes are possible given volatility and low float, the risk/reward skews heavily negative as secular headwinds intensify.

Pitch Summary:
Bumble is an online dating app where women initiate conversations, positioned against peers like Tinder, Hinge, and Grindr. The stock has rallied recently but remains at all-time lows, and the author recommends a short. The turnaround plan, led by the returning founder-CEO, centers on cutting OpEx, eliminating bots, and improving user experience. However, the thesis resembles failed turnarounds like Nextdoor (KIND), which struggled with structural user dissatisfaction despite similar strategies. Bumble’s model may inherently disadvantage men, leading to churn and limiting long-term engagement, while changes risk diluting the brand’s identity. Recurring revenues may be overstated given churn-driven re-downloads. More significantly, the author argues that AI poses existential risk to online dating, as younger males increasingly gravitate toward AI companionship or avatars (with OnlyFans given as a parallel). While quarterly results may show temporary improvement, the structural and terminal value risks suggest limited turnaround potential. Acquisition is also seen as unlikely, as competitors like Hinge or AI-driven apps capture churned users.

BSD Analysis:
Bumble is positioned as a structurally flawed online dating platform facing both user-experience constraints and long-term disruption from AI. While management’s turnaround plan has surface-level appeal, the deeper issues of user churn and lack of differentiation are difficult to fix. With AI-driven alternatives accelerating, the investment case skews negatively despite occasional trading volatility.

Pitch Summary:
Journey Medical is poised for growth with its new product, Emrosi, an oral treatment for rosacea that launched in April 2025. The company has a strong leadership team with experience from Medicis, and Emrosi is expected to generate significant revenue due to its early prescription traction and a robust commercial strategy.

BSD Analysis:
Journey Medical's leadership, led by CEO Claude Maraoui, brings extensive experience from Medicis, ensuring a well-executed commercialization strategy for Emrosi. The company is already break-even with its base business, and Emrosi's revenue is highly accretive, dropping directly to the bottom line. With a dual-site manufacturing strategy and strong early payer traction, Journey is well-positioned to achieve its peak U.S. sales target of $200M+. The company's focus on execution and commercial discipline, along with its strategic alignment through equity ownership, supports a sustainable growth trajectory. As payer coverage expands and prescription volume increases, Journey's financial performance is expected to improve further.

Pitch Summary:
CDW Corporation has demonstrated strong financial performance with a 6.7% year-over-year increase in net sales and a 10.6% rise in adjusted EPS for Q1 2025. However, the growth was partly driven by front-loaded orders due to anticipated tariff increases, which may not sustain in subsequent quarters. The company faces challenges from potential tariff impacts, federal budget constraints, and the need to maintain momentum in its services segment. Given these uncertainties, the stock is currently a hold.

BSD Analysis:
CDW's valuation at a trailing P/E of ~21.8x and forward P/E of 22x suggests a fair pricing relative to its earnings growth and free cash flow generation. The EV/EBITDA multiple of ~14x aligns with industry norms, though slightly above value-oriented opportunities. The company's shift towards higher-margin services, such as Mission Cloud, is promising but faces competition and potential cyclicality. Federal IT spending cuts and tariff-related demand distortions present risks to near-term performance. Investors should monitor Q2 results for clarity on demand trends and margin stability before considering a position change. The stock's P/S ratio of 1.1x reflects its lean operations but remains at a discount to sector medians, indicating potential for revaluation if growth stabilizes.

Pitch Summary:
Core Natural Resources (CNR) presents a complex investment case following its formation from the merger of two significant coal companies. Despite having strategic assets and a strong logistics network, CNR faces challenges such as integration costs and operational disruptions. The company's financials show a strong liquidity position and a focus on shareholder returns through buybacks and dividends, but profitability and margins lag behind industry averages. Given these factors, a hold position is recommended until CNR demonstrates more consistent financial performance.

BSD Analysis:
CNR's valuation metrics reveal a mixed picture. The company's P/E TTM of 22.89x is higher than the sector average, indicating a market premium on recent gains, yet the P/E FWD aligns more closely with sector norms, suggesting stabilization expectations. The EV/Sales ratio suggests a relatively cheap valuation compared to historical revenues, but the elevated EV/EBITDA indicates a risk premium due to lower operating profitability. CNR's revenue growth is a positive aspect, with a YoY increase of 11.29% and a forward projection of 20.88%, signaling commercial expansion despite operational hurdles. However, the company's profitability metrics, such as operating and net margins, are significantly below sector averages, highlighting the need for improved cost management and operational efficiency. The coal market's inherent volatility, coupled with environmental policy risks, adds further uncertainty to CNR's outlook. Investors should monitor coal price trends and CNR's ability to leverage its assets effectively to enhance profitability.

Pitch Summary:
Global Water Resources is strategically positioned to benefit from the intensifying water crisis in Arizona, a state experiencing rapid population growth and increasing water scarcity. The company's unique Total Water Management model, which integrates sewage treatment and water supply, provides a competitive edge in a market with high regulatory barriers. Despite a high P/E ratio of 55x, the company's growth prospects are supported by its exclusive focus on Arizona, where water demand is projected to exceed supply significantly. This positions GWRS as a compelling investment with a potential 33% upside over the next 18-24 months.

BSD Analysis:
Global Water Resources operates in a high-growth region with a projected population increase of 18% by 2040, which will likely drive demand for its services. The company's business model, which does not require adaptation to the Total Water Management approach, gives it an advantage over peers who are still transitioning. Despite recent revenue stagnation due to non-recurring projects, core revenue has shown a 5% growth, indicating underlying business strength. The company's financial stability is further supported by a solid operational cash flow, which comfortably covers its dividend payouts. With an EV/EBITDA multiple expected to stabilize around 16.5x, and potential tariff adjustments that could enhance margins, GWRS is well-positioned to capitalize on the ongoing water crisis. The stock's downside risk is mitigated by a strong support line and a 3% dividend yield, making it an attractive investment with limited downside potential.

Pitch Summary:
Clipper Realty is currently undervalued, trading at a depressed P/AFFO multiple due to market overreaction to risks such as potential rent control and the re-leasing of 250 Livingston Street. The company's AFFO is growing, supported by high occupancy rates and strong rental demand. With a potential upside of 80% based on a more reasonable P/AFFO multiple, Clipper Realty presents a compelling investment opportunity.

BSD Analysis:
Clipper Realty's AFFO growth is driven by a robust rental market, with 99% occupancy and rising rents in New York City. The company's leverage, while high, is manageable given the long maturity dates on its debt and the potential for refinancing at lower rates. The risk of rent control under New York City's new mayor could impact future AFFO growth, but the company's diversified portfolio and strategic asset sales, such as the 10 West 65th Street property, provide financial flexibility. The potential resolution of the 250 Livingston Street lease could further enhance AFFO, while the current dividend yield of 9% offers attractive income. Overall, Clipper Realty's valuation appears attractive, with significant upside potential if market conditions stabilize and management successfully navigates the current challenges.